Drug Trial Radar · NCT07502287
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Mar 14, 2027
Study completion Jun 17, 2028
Sponsor
- Lead sponsor
- Beijing BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 months, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates preliminary activity
Conditions
- Relapsed Neuroblastoma
- Refractory Neuroblastoma
- High-Risk Neuroblastoma
- Ganglioneuroblastoma
Interventions
EB-DTNB-NKBiological
Allogeneic, cord blood-derived NK cells engineered with a dual-target CAR recognizing GD2 and B7-H3 (CD276), with IL-15 support and an inducible safety switch; administered intravenously on Day 0 with optional repeat dosing on Days 7 and 14 if tolerated.
FludarabineDrug
Lymphodepleting chemotherapy administered before CAR-NK infusion according to the protocol-defined conditioning regimen.
CyclophosphamideDrug
Lymphodepleting chemotherapy administered before CAR-NK infusion according to the protocol-definedb conditioning regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) after first CARNK infusion, using protocol-defined DLT criteria.Time frame: 28 days
- Incidence and severity of treatment-emergent adverse eventsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.